Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflamma... BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Mehr anzeigen
BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 BX004 Phase 2b study in Cystic Fibrosis (CF) is now...
NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.2457 | -31.9090909091 | 0.77 | 0.77 | 0.48 | 85660 | 0.54333614 | CS |
| 4 | -0.371 | -41.4386239249 | 0.8953 | 0.924 | 0.48 | 161715 | 0.741191 | CS |
| 12 | -0.7657 | -59.3565891473 | 1.29 | 1.31 | 0.48 | 82440 | 0.83929623 | CS |
| 26 | -3.1257 | -85.6356164384 | 3.65 | 4.9 | 0.48 | 198999 | 2.05833992 | CS |
| 52 | -3.4287 | -86.7366557045 | 3.953 | 8.55 | 0.48 | 817028 | 5.64328023 | CS |
| 156 | -19.3757 | -97.3653266332 | 19.9 | 21.4 | 0.48 | 382610 | 5.54209254 | CS |
| 260 | -78.3017 | -99.3348641311 | 78.826 | 110.5 | 0.48 | 244472 | 8.66378898 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| MSTZT Rex 2X Inverse MSTR Daily Target ETF | US$ 0,9467 (-11,52%) | 795,18M |
| NVDQT Rex 2X Inverse NVIDIA Daily Target ETF | US$ 3,22 (6,62%) | 56,33M |
| FXIiShares China Large Cap | US$ 29,69 (-2,17%) | 53,99M |
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 28,49 (0,00%) | 50,44M |
| SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 6,035 (-0,74%) | 49,69M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
